Hi everyone
Answer 2️⃣6️⃣9️⃣9️⃣
The patient has been taking inadequate doses of thyroxine. The aim of T4 therapy in patients with papillary carcinoma of the thyroid is to suppress TSH to undetectable concentrations; this has not been achieved in this patient. Compliance should be verified and the need for an increase in T4 dose ascertained.
In patients who have undergone total thyroidectomy and in whom TSH is <0.01 mU/L, thyroglobulin should be undetectable. This patient has residual thyroid tissue (she only has had a partial thyroidectomy) and she has detectable circulating TSH that will stimulate thyroglobulin production from the thyroid remnant. It is thus impossible to determine from these results if the thyroglobulin is originating from the thyroid remnant or a recurrent tumour. Thyroglobulin was later found to be undetectable when the patient's TSH was <0.01 mU/L and no further action was required other than continued annual follow-up.
باسپاس فراوان از همکاران گرامی اقایان و خانم ها
جعفری
رضایی
آرضابک
عبادیان
عبدلی
@QandA_lab
1August 24, 2026 303 1
